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ObituaryChris Marshall (1949–2015)Chris MarshallChris Marshall, who died on August 8 at
age 66, was a world-renowned cell biolo-
gist best known for his pioneering contri-
butions to oncogene research and to cell
signaling via GTPases, especially to our
understanding of tumor cell signaling
through the Ras-Raf-Mek-Erk pathway.
He spent the whole of his independent
research career at the Chester Beatty
Laboratories of the Institute of Cancer
Research (ICR) in London, where he was
Professor of Cell Biology and Head of
the Division of Cancer Biology. Not long
after his arrival at ICR in 1980, he estab-
lished a close and superbly successful
research partnership with Alan Hall, who
predeceased him by three months (Cell
161, pp. 1239–1240, 2015). It is poignant
that Chris, who spoke so eloquently at
Alan’s funeral, was to follow so soon and
that he succumbed to colon cancer, one
of the tumors that most frequently carries
RAS mutations. The international cancer
research community keenly feels the
dual loss of Chris and Alan.
Christopher John Marshall was born
in Birmingham on January 19, 1949 to
James and Lillian Marshall and later lived
in Coventry, where he attended King
Henry VIII School. His father was a works
manager for Massey-Ferguson, the
tractor manufacturers, and there was not
a strong science tradition in his family.
He won a scholarship to Churchill Col-
lege, Cambridge to study natural sci-
ences, specializing in genetics. As a grad-
uate student, he joined Henry Harris’s
laboratory at the Sir William Dunn School
of Pathology in Oxford, where he gained
his DPhil in 1973. His doctoral studies
concerned somatic cell genetics of hy-
brids between human and murine cells
after Harris and Watkins developed an
efficient method of cell fusion using
inactivated Sendai virus. He used spe-
cies-specific chromosome banding to
examine chromosome segregation and
studied the control of expression of ribo-
somal RNA in heterokaryons. His experi-
ence of somatic cell genetics served him
well when he joined Sammy Franks’
experimental pathology laboratory at the
Imperial Cancer Research Fund Labora-
tories (now part of the Francis Crick
Institute) and became interested in sup-pression of the malignant phenotype in
normal-tumor cell hybrids and in markers
of neoplastic transformation in human
carcinomas. He continued this interest
in tumor suppression during a second
post-doctoral position with Ruth Sager
at the Dana-Farber Cancer Center at Har-
vard Medical School.
Chris Marshall’s illustrious career took
off in 1980, when he joined the ICR to
establish his own team. With the grant
that he won from the Cancer Research
Campaign, now part of Cancer Research
UK (CRUK), he planned to continue
studies of tumor suppression, which was
still a nascent field. However, he soon
joined forces with Alan Hall in Robin
Weiss’s laboratory to study oncogenes
instead. Alan introduced the relatively
new recombinant DNA techniques to the
ICR, and the two of them embarked on a
project searching for human oncogenes
by DNA transfection into murine NIH 3T3
cells. This technique had recently been
shown to work for murine tumors, and it
was the natural next step to apply it to hu-
man tumors. Marshall and Hall tried DNA
transfer from many human neoplastic cell
lines without success and were on the
point of abandoning the project when
they obtained transformed cells using
DNA from two human sarcoma cell lines.
They successfully cloned the human
gene responsible for cell transformation
to reveal a novelmember of theRASonco-
gene family,NRAS.HRAS andKRASwere
originally identified as retroviral onco-Cell 162, Sepgenes, but NRAS had not previously
been characterized. The breakthrough
exemplified two facets of Chris’s aptitude
for discovery: boldness to pursue a new
avenue distinct from the original purpose
of his research grant and perseverance.
The discovery of NRAS led to Chris’s
long-standing interest in cell signaling
through the activation of small GTPases.
About 12% of human tumors bear muta-
tions in one of the three RAS genes that
lead to constitutive signaling. Marshall
and Hall made leading contributions to
elucidating how Ras proteins transmit
signals from the cell membrane through
many steps to the nucleus. They played
a major role in unraveling the signaling
cascade that leads to cell proliferation
via the Map-kinase pathway, and Chris’s
team showed that the p21 Ras protein
must become farnesylated and thereby
associate with membranes to function in
the signaling pathway. They elucidated
how Ras activates Raf, which acts on
Mek and in turn activates Map-kinase,
and showed that mutated NRAS results
in overstimulation of this pathway.
Some years later, Chris employed
his deep insight into the pathway to
contribute to the first success of the Well-
come Trust Sanger Institute’s Cancer
Genome Project, in which Mike Stratton
and his colleagues showed that themajor-
ity ofmelanomas testedcarried amutation
inBRAF. TogetherwithRichardMarais, he
explored the biological consequences of
themutation and he returned to the bench
to use his skills at transfection to demon-
strate that the V600E mutant of BRAF is
a transforming oncogene.
Chris was no ivory tower scientist.
He adhered to Sydney Brenner’s dictum
that there is no real distinction between
basic and applied research—only be-
tween good and mediocre research. He
clearly saw the potential of exploiting the
new knowledge of signal transduction
for drug discovery. It was a source of
great pleasure to him that four new clas-
ses of drug that target the pathway he
did so much to elucidate have entered
the clinic and that two of them are in
widespread use.
During the past decade, Chris became
interested in tumor cell motility and
metastasis, and he extended his research
into signaling pathways downstream of
other GTPases such as Rac and Rho. Hetember 10, 2015 ª2015 Elsevier Inc. 1177
showed that these pathways control two
alternate modes of cell movement, which
differ in their requirement for extracellular
proteolysis, and demonstrated the key
role of the Rho effector kinase Rock.
Ever alert to the translational agenda,
one of his most recent papers reports
that Rock inhibitors block melanoma cell
motility, invasion, and metastasis in an
animal model.
Tackling difficult problems came natu-
rally to Chris, provided that they were
potentially soluble. He exhibited great en-
ergy in both professional and recreational
life, approaching science and cycling with
equal enthusiasm. Vigorous scientific dis-
cussion with colleagues did not end upon
leaving the lab for the day but often
continued in neighboring pubs. During
his 35 years at ICR, Chris took on many
roles, most notably that of Director of
Research. His forceful championing of
the translational agenda and his insis-
tence that such work could, and should,
be of the highest quality was of great
importance to the success of the ICR
and its partner, the Royal Marsden Hospi-
tal. He was mentor to numerous young1178 Cell 162, September 10, 2015 ª2015 Elscientists who went on to successful
research careers elsewhere, including
Karen Vousden, Director of the CRUK
Beatson Institute for Cancer Research in
Glasgow, and Richard Marais, Director
of the CRUK Manchester Institute, to
name but two.
In contrast to enjoying the respect that
he received from his scientific and aca-
demic peers, Chris did not regard himself
as a pillar of the British ‘‘establishment.’’
When he joined the ranks of worthy peo-
ple with an entry in Who’s Who, he gave
his ‘‘club’’ as Norwood Paragon Cycling,
and it seems to us that that summed him
up nicely.
Chris held his opinions strongly and
could at times appear acerbic, yet he
was a kind, loyal, and helpful colleague.
He sat on various national and interna-
tional panels with distinction. He was
elected amember of the EuropeanMolec-
ular Biology Organization in 1993, a
Fellow of the Royal Society in 1995, and
in 1998 was awarded its Buchanan
Medal. He was a founding member of
the Academy of Medical Sciences. This
year he received the Centenary Award ofsevier Inc.the Biochemical Society, having previ-
ously been awarded its Novartis Prize.
Throughout most of his career, Chris
was supported by Cancer Research UK
and its precursor organizations; he held
the coveted Gibb Fellowship and recently
won its Lifetime Achievement Award. For
the past three years, Chris chaired
CRUK’s Science Funding Committee.
Not least, Chris served continuously for
23 years on the editorial board of Cell!
Chris is survived by Lesley, his wife, and
by Vivien, his first wife with whom he had
three children. He delighted in his four
grandchildren and the time they were
able to spend together.Peter W.J. Rigby1,*
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